Novasep and instrAction Expand Alliance to Include Taxane Purification

By Novasep, PRNE
Wednesday, February 9, 2011

Companies Will Develop Solutions to Change Manufacturing Paradigm for New and Generic Anti-cancer Compounds

POMPEY, France and LUDWIGSHAFEN, Germany, February 10, 2011 - Novasep, a leading supplier of manufacturing solutions to the
life science industries, and instrAction, a manufacturer of innovative
chromatographic stationary phases for API purification processes, today
announce they have expanded their worldwide strategic alliance to include the
purification of taxanes, a well-known class of anti-cancer compounds.

This extended collaboration enables Novasep to develop and
operate or supply optimized large-scale chromatography processes for
cost-effective purification of taxane-based active pharmaceutical ingredients
(APIs) and intermediates. The two companies announced a strategic alliance
covering non-chiral chromatography in July 2010. The extended relationship
means Novasep adds enhanced taxane capabilities to its extensive range of
manufacturing solutions for life science industries. Novasep customers will
benefit from the collaboration as they will be able to access a
cost-effective one-step purification solution for their taxane-based APIs.

instrAction has synthesized API-selective stationary phases
among their 3,000-phase library based on its proprietary technology, which
have shown a strong potential for taxane purification. Novasep can develop a
multi-step synthesis and optimize purification steps using instrAction's set
of taxane-selective chromatographic stationary phases. Novasep can then scale
up the optimized process and produce the API for clinical and commercial
purposes. Alternatively, Novasep can supply the developed process to its
customers with performance guarantees, integrating Novasep's leading
Prochrom(R) HPLC columns and systems and instrAction's selective stationary
phases. For mature or generic APIs, Novasep and instrAction can additionally
file and license application patents to extend the protection of their
customers' products.

Novasep develops and manufactures taxane-based APIs and
advanced intermediates at its FDA inspected and SafeBridge certified Le Mans
site in France, specialized in highly potent API (HPAPI) synthesis and

"Thanks to instrAction's highly selective chromatographic
stationary phases and Novasep's 20 years experience in taxane synthesis and
purification, we are looking to see a paradigm shift in solutions for our
customers worldwide as a result of this collaboration," says Rene De Vaumas,
executive vice president in charge of Novasep Synthesis' business

"We are delighted about our extended collaboration with
Novasep, a leader in taxane synthesis and purification," said Dr. Thomas
, CEO of instrAction GmbH. "It is a further important milestone to
implement the instrAction technology in industrial downstream processes. We
are very confident that it will be broadly applied to the industrial
purification of APIs in the future."

About Novasep

Novasep develops, markets and operates innovative technologies
providing life science industries with safe and cost-effective production of
active molecules. The global manufacturing solutions offered by Novasep
include process development services; purification equipment and systems;
contract manufacturing services; and complex active molecules. The
applications of Novasep's offering cover the pharmaceutical,
biopharmaceutical, food, functional ingredients and bio-industries markets.

About instrAction

instrAction, founded in 1997 by Dr. Klaus Gottschall and
located at the BASF site in Ludwigshafen, develops and manufactures
"Instruction(R) Receptor Phases" as novel API-selective resins for
chromatography. The Instruction(R) technology enables the immobilization of a
wide variety of functional ligands on a polymer network, coated on very
different porous backbone materials. Small molecules as well as substances
with high molecular weight are separated by highly selective reversible
interactions. The high selectivity of an instrAction stationary phase is
thereby reached by multivalent-multimodal interactions between target
molecule and the functional ligands of the phase, similar to the lock-and-key

Press & media relations: For Novasep, Jean Blehaut, Jean.blehaut at, Tel: +33-383-49-70-99; For instrAction, Dr. Bjorn Degel, degel at, Tel: +49-621-598-0515

will not be displayed